204 related articles for article (PubMed ID: 15308953)
21. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users.
Bruneau J; Roy E; Arruda N; Zang G; Jutras-Aswad D
Addiction; 2012 Jul; 107(7):1318-27. PubMed ID: 22248184
[TBL] [Abstract][Full Text] [Related]
22. High hepatitis C incidence in new injecting drug users: a policy failure?
Maher L; Li J; Jalaludin B; Chant KG; Kaldor JM
Aust N Z J Public Health; 2007 Feb; 31(1):30-5. PubMed ID: 17333606
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus seroconversion among young injection drug users: relationships and risks.
Hahn JA; Page-Shafer K; Lum PJ; Bourgois P; Stein E; Evans JL; Busch MP; Tobler LH; Phelps B; Moss AR
J Infect Dis; 2002 Dec; 186(11):1558-64. PubMed ID: 12447730
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis C antibody prevalence among Mexico City prisoners injecting legal and illegal substances.
Silverman-Retana O; Serván-Mori E; McCoy SI; Larney S; Bautista-Arredondo S
Drug Alcohol Depend; 2017 Dec; 181():140-145. PubMed ID: 29054033
[TBL] [Abstract][Full Text] [Related]
25. Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of misuse in a prospective cohort of street youth.
Hadland SE; DeBeck K; Kerr T; Feng C; Montaner JS; Wood E
BMJ Open; 2014 Jul; 4(7):e005419. PubMed ID: 25052173
[TBL] [Abstract][Full Text] [Related]
26. Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.
Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J;
J Viral Hepat; 2017 Sep; 24(9):733-741. PubMed ID: 28256027
[TBL] [Abstract][Full Text] [Related]
27. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence.
Rezza G; Sagliocca L; Zaccarelli M; Nespoli M; Siconolfi M; Baldassarre C
Scand J Infect Dis; 1996; 28(1):27-9. PubMed ID: 9122628
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use.
Des Jarlais DC; Arasteh K; Feelemyer J; McKnight C; Barnes DM; Perlman DC; Uuskula A; Cooper HLF; Tross S
Drug Alcohol Depend; 2018 Nov; 192():74-79. PubMed ID: 30243142
[TBL] [Abstract][Full Text] [Related]
29. Syringe exchange and risk of infection with hepatitis B and C viruses.
Hagan H; McGough JP; Thiede H; Weiss NS; Hopkins S; Alexander ER
Am J Epidemiol; 1999 Feb; 149(3):203-13. PubMed ID: 9927214
[TBL] [Abstract][Full Text] [Related]
30. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area.
Thiede H; Hagan H; Murrill CS
J Urban Health; 2000 Sep; 77(3):331-45. PubMed ID: 10976608
[TBL] [Abstract][Full Text] [Related]
31. Gender influences on hepatitis C incidence among street youth in a Canadian setting.
Puri N; DeBeck K; Feng C; Kerr T; Rieb L; Wood E
J Adolesc Health; 2014 Dec; 55(6):830-4. PubMed ID: 25240449
[TBL] [Abstract][Full Text] [Related]
32. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 2: Preliminary UK estimates of prevalent injection-related hepatitis C carriers, and derivation of progression rates to liver cirrhosis by gender and age at hepatitis C virus infection.
Bird SM; Goldberg DJ; Hutchinson SJ
J Epidemiol Biostat; 2001; 6(3):267-77; discussion 279-85. PubMed ID: 11437089
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C incidence--a comparison between injection and noninjection drug users in New York City.
Fuller CM; Ompad DC; Galea S; Wu Y; Koblin B; Vlahov D
J Urban Health; 2004 Mar; 81(1):20-4. PubMed ID: 15047780
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C virus infection in South Australian prisoners: seroprevalence, seroconversion, and risk factors.
Miller ER; Bi P; Ryan P
Int J Infect Dis; 2009 Mar; 13(2):201-8. PubMed ID: 18790659
[TBL] [Abstract][Full Text] [Related]
35. Benzodiazepine Use and Hepatitis C Seroconversion in a Cohort of Persons Who Inject Drugs.
Bach P; Walton G; Hayashi K; Milloy MJ; Dong H; Kerr T; Montaner J; Wood E
Am J Public Health; 2016 Jun; 106(6):1067-72. PubMed ID: 26985601
[TBL] [Abstract][Full Text] [Related]
36. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects.
Galeazzi B; Tufano A; Barbierato E; Bortolotti F
Liver; 1995 Aug; 15(4):209-12. PubMed ID: 8544644
[TBL] [Abstract][Full Text] [Related]
38. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China.
Garten RJ; Lai S; Zhang J; Liu W; Chen J; Vlahov D; Yu XF
Int J Epidemiol; 2004 Feb; 33(1):182-8. PubMed ID: 15075167
[TBL] [Abstract][Full Text] [Related]
39. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.
van Beek I; Dwyer R; Dore GJ; Luo K; Kaldor JM
BMJ; 1998 Aug; 317(7156):433-7. PubMed ID: 9703523
[TBL] [Abstract][Full Text] [Related]
40. Low risk for hepatitis C seroconversion in methadone maintenance treatment.
Peles E; Schreiber S; Rados V; Adelson M
J Addict Med; 2011 Sep; 5(3):214-20. PubMed ID: 21844836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
